The Collaborative Science-Research & Operations (CSR&O) welcomes you to the Bristol-Myers Squibb Investigator Sponsored Research (ISR) application website. ISR is also referred to as Investigator Initiated Research, Investigator Sponsored Trials, and Investigator Initiated Trials. This website provides information to investigators interested in submitting an ISR proposal. Please select the appropriate option below.
Questions about Investigator-Sponsored Research, click here.
Questions about being a Bristol-Myers Squibb Sponsored Investigator, click here.
Expanded Access Program (Compassionate Use) Investigator Requests, click here.
Investigator Guide for How to Apply, click here.
For Clinical Trial Data Sharing, click here.
Effective February 1, 2014, the Investigator-Sponsored Research application process for all Bristol-Myers Squibb Diabetes-related requests has transitioned to AstraZeneca. Please submit all new Clinical Investigator-Sponsored Clinical and Non-Interventional research proposals to AstraZeneca here.
Please also visit the AstraZeneca portal for Externally Sponsored Research to find out more information about the areas of interest for the Diabetes compounds.
For more inquiries regarding the submission process please refer to our training centre.
Please submit all new requests for Material (MTA) and Preclinical research proposals to AstraZeneca’s central mailbox: preclinical-diabetesISS@astrazeneca.com
As of September 22, 2014, this AstraZeneca process should be followed for Diabetes-related studies worldwide including in China.
For investigators interested in Clinical Research.
For investigators interested in research to increase the understanding of diseases, disease management, or drug use and effects in patient populations in a real-life setting.
For researchers interested in obtaining compounds/materials for laboratory and/or animal research.
For investigators belonging to Co-Ops and Networks interested in Clinical Research.
For investigators interested Pediatric Clinical Research.
For investigators participating in the Bristol-Myers Squibb International Immuno-Oncology Network.